Navigating the Challenges of Prescribing PCSK9 Inhibitors in Patients with Persistent Elevated LDL-C


Navigating the Challenges of Prescribing PCSK9 Inhibitors in Patients with Persistent Elevated LDL-C

Topic: Cardiology
Relevant Terms: Cardiometabolic, Lipidology
Primary Audience: Lipidologists, endocrinologists, and cardiologists, nurse practitioners, physician assistants, registered dietitians, advanced practice registered nurses, registered nurses, and pharmacists who are members of the NLA, as well as a national cohort of providers who manage patients with high LDL cholesterolemia
Launch Date: 19-Sep-17
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: 19-Sep-18
Curriculum Name: Navigating the Challenges of Prescribing PCSK9 Inhibitors in Patients with Persistent Elevated...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Incorporate PCSK9 inhibitors into the management of high LDL cholesterolemia based on their distinct mechanism of action and favorable safety and efficacy profiles, and appropriate indications for use
  2. Effectively navigate payer systems when managing patients with high LDL cholesterol with PCSK9Is to promote the likelihood of reimbursement
  3. Discuss strategies to improve the knowledge, skills or performance of the healthcare team


    James Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNLA (Chair)
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for CVD Prevention
    New York, NY
    Mary Katherine Cheeley, PharmD, BCPS, CLS
    Clinical Pharmacist Specialist
    Grady Health System
    Atlanta, GA
    Winston Wong, PharmD
    W-Squared Group
    Longboat Key, FL
    Accreditation Statement
    CME credit provided by the National Lipid Association
    In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and RMEI Medical Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Physician Credit Designation Statement 
    The National Lipid Association designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity. 
    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
    The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
    Pharmacist Accreditation Statement
    Universal Activity Number 0624-9999-17-056-H01-P (Application)
    This activity has been approved for 1.0 contact hour(s) (.1 CEUs) of the Accreditation Council for Pharmacy Education.
    The maximum number of hours awarded for this CE activity is 1.0 contact hours. 
    For the advanced practice nurse, this activity has 0.3 contact hour(s) of pharmacotherapy content.
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • James Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNLA, has affiliations with Aegerion, Amarin, Amgen, Kinder Pharm, and Recombine (Consultant); Akcea, Alexion, Amgen, Astra Zeneca, Gemphire Pharma, New Haven Pharma, Regeneron, and Sanofi (Advisory Board); Alexion, Amgen, Astra Zeneca, Merck, Regeneron, and Sanofi (Speaker); Aegerion and Pfizer (Research); and Aegerion (Clinical Trials). 
    • Mary Katherine Cheeley, PharmD, BCPS, CLS, has affiliations with Amgen (Consultant); Regeneron (Research); Regeneron/Sanofi (Speaker); and Regeneron/Sanofi (Advisory Board).
    • Winston Wong, PharmD, has no affiliations with commercial interest relative to the content to disclose.
    RMEI Medical Education, LLC
    • Dan Hayes, MD, has no affiliations with commercial interests relative to the content to disclose.
    • Katherine Mann, PharmD, has affiliations with Otsuka (spouse is a consultant and on the board of directors to Otsuka Pharmaceutials, USA).
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
    National Lipid Association
    • Allison Fellers has no affiliations with commercial interests relative to the content to disclose.
    • Amina Resheidat has no affiliations with commercial interests relative to the content to disclose.
    • John Casey Elkins, DNP, NP-C, Med, CLS, FNLA, has received fees as a speaker for Sanofi/Regeneron.  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.  
    Estimated time to complete:  1 hour  
    Media: Internet
    There is no fee for this educational activity.

    This activity is jointly provided by RMEI Medical Education, LLC, and the National Lipid Association (NLA). This activity is supported by an independent medical educational grant from Sanofi US and Regeneron Pharmaceuticals.  

    To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. 

    For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.
    If you have any questions relating to the accreditation of this activity, please contact
    Click here for NLA’s Privacy Statement.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.